- Home
- JXJT vs MTEM Comparison
JXJT vs MTEM Comparison
Compare JXJT & MTEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JXJT
- MTEM
- Stock Information
- Founded
- JXJT 2012
- MTEM 2001
- Country
- JXJT China
- MTEM United States
- Employees
- JXJT N/A
- MTEM N/A
- Industry
- JXJT Apparel
- MTEM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JXJT Consumer Staples
- MTEM Health Care
- Exchange
- JXJT Nasdaq
- MTEM Nasdaq
- Market Cap
- JXJT 11.5M
- MTEM 9.7M
- IPO Year
- JXJT 2012
- MTEM N/A
- Fundamental
- Price
- JXJT $1.57
- MTEM $0.71
- Analyst Decision
- JXJT
- MTEM
- Analyst Count
- JXJT 0
- MTEM 0
- Target Price
- JXJT N/A
- MTEM N/A
- AVG Volume (30 Days)
- JXJT 36.7K
- MTEM 13.4M
- Earning Date
- JXJT 11-01-2024
- MTEM 11-11-2024
- Dividend Yield
- JXJT N/A
- MTEM N/A
- EPS Growth
- JXJT N/A
- MTEM N/A
- EPS
- JXJT 0.48
- MTEM N/A
- Revenue
- JXJT $31,840,588.00
- MTEM $25,470,000.00
- Revenue This Year
- JXJT N/A
- MTEM N/A
- Revenue Next Year
- JXJT N/A
- MTEM N/A
- P/E Ratio
- JXJT $3.40
- MTEM N/A
- Revenue Growth
- JXJT N/A
- MTEM N/A
- 52 Week Low
- JXJT $1.04
- MTEM $0.30
- 52 Week High
- JXJT $8.51
- MTEM $6.48
- Technical
- Relative Strength Index (RSI)
- JXJT 38.73
- MTEM 38.68
- Support Level
- JXJT $1.40
- MTEM $0.31
- Resistance Level
- JXJT $1.75
- MTEM $1.34
- Average True Range (ATR)
- JXJT 0.14
- MTEM 0.14
- MACD
- JXJT -0.04
- MTEM -0.05
- Stochastic Oscillator
- JXJT 32.08
- MTEM 34.48
About JXJT JX Luxventure Limited
JX Luxventure Ltd is engaged in the tourism sector and supplying related products, including technology solutions, to business partners in China, both online and offline. The company operates in three segments Airline tickets and tourism services, Software Solutions for Tourism Cross-border operation, and Tourism Cross-border Merchandise. The majority of the group revenue is generated from Tourism products.
About MTEM Molecular Templates Inc.
Molecular Templates Inc is a clinical-stage biopharmaceutical company focused on developing therapeutic agents that selectively target tumor cells for the treatment of individuals living with cancer. Its pipeline products are MT-6402, MT-8421 and MT-0169.